https://scholars.lib.ntu.edu.tw/handle/123456789/626873
標題: | Dipeptidyl peptidase-4 inhibitor use is not associated with acute pancreatitis in high-risk type 2 diabetic patients a nationwide cohort study | 作者: | CHIA-HSUIN CHANG JOU-WEI LIN Chen, Shu-Ting Lai, Mei-Shu LEE-MING CHUANG YI-CHENG CHANG |
關鍵字: | GLP-1 RECEPTOR ACTIVATION; INCRETIN-BASED DRUGS; BETA-CELL FUNCTION; POPULATION; EXENATIDE; EXENDIN-4; CANCER; METAANALYSIS; SITAGLIPTIN; THERAPIES | 公開日期: | 二月-2016 | 出版社: | LIPPINCOTT WILLIAMS & WILKINS | 卷: | 95 | 期: | 7 | 來源出版物: | Medicine | 摘要: | To analyze the association between use of DPP-4 inhibitors and acute pancreatitis in high-risk type 2 diabetic patients. A retrospective nationwide cohort study was conducted using the Taiwan National Health Insurance claim database. The risk associated with sitagliptin was compared to that with acarbose, a second-line antidiabetic drug prescribed for patients with similar diabetes severity and with a known neutral effect on pancreatitis. Between January 1, 2009 and December 31, 2010, a total of 8526 sitagliptin initiators and 8055 acarbose initiators who had hypertriglyceridemia or prior hospitalization history for acute pancreatitis were analyzed for the risk of hospitalization due to acute pancreatitis stratified for baseline propensity score. In the crude analysis, sitagliptin was associated with a decreased risk of acute pancreatitis (hazard ratio [HR] 0.74; 95% confidence interval [CI]: 0.62-0.88) compared to acarbose in diabetic patients with prior history of hospitalization for pancreatitis or hypertriglyceridemia. The association was abolished after stratification for propensity score quintiles (adjusted HR 0.95; 95% CI: 0.79-1.16). Similar results were found separately in both patients' histories of prior hospitalization of acute pancreatitis (adjusted HR 0.97; 95% CI: 0.76-1.24) and those with hypertriglyceridemia (adjusted HR 0.86; 95% CI: 0.65-1.13). No significant association was found for different durations or accumulative doses of sitagliptin. In the stratified analysis, no significant effect modification was found in relation to patients' characteristics. Use of sitagliptin was not associated with an increased risk of acute pancreatitis in high-risk diabetic patients with hypertriglyceridemia or with history of acute pancreatitis. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/626873 | ISSN: | 0025-7974 | DOI: | 10.1097/MD.0000000000002603 |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。